-+ 0.00%
-+ 0.00%
-+ 0.00%

VIR BIOTECHNOLOGY GRANTS NORGINE EXCLUSIVE COMMERCIAL LICENSE TO CHRONIC HEPATITIS DELTA TREATMENT CANDIDATE IN EUROPE, AUSTRALIA & NEW ZEALAND, INCLUDING GLOBAL COST SHARING AGREEMENT FOR ONGOING ECLIPSE CLINICAL DEVELOPMENT PROGRAM

Reuters·12/16/2025 21:05:00

Please log in to view news